MC38-hIL1β
品系基本信息
*使用本品系發(fā)表的文獻需注明: MC38-hIL1β cell line (Cat. NO. NMC-250201) was purchased from Shanghai Model Organisms Center, Inc..
驗證數(shù)據(jù)
Fig1.?The anti-hIL1β mAb Canakinumab alone or in combination with Tecentriq significantly inhibited the growth of MC38-hIL1β tumors in C57mice, demonstrating that this model is suitable for evaluating the in vivo efficacy of anti-hIL1β mAb alone and in combination with PD-1/PD-L1 antibodies.?
Fig. 2 Blinatumomab injections were repeated daily for 5 days and immune cells in the PB of mice after therapy were measured by flow cytometry.
你也可能感興趣
Tamoxifen誘導Cre-ERT2小鼠 使用指南
Cre-ERT2在無Tamoxifen誘導的情況下，在細胞質內處于無活性狀態(tài)；當Tamoxifen誘導后，Tamoxifen的代謝產物4-OHT（雌激素類似物）與ERT結合，可使Cre-ERT2進核發(fā)揮Cre重組酶活性。
查看
